ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed
A securities fraud class action has been filed against ADMA Biologics (NASDAQ: ADMA) for allegedly making false statements about its financial condition and business practices. The lawsuit claims the company engaged in undisclosed related-party transactions, channel stuffing, and lacked adequate internal controls. A Culper Research short-seller report in March 2026 exposed these allegations, causing the stock to plunge 31.6% over two trading days, with further declines following an ADMA response and analyst downgrade.
Read the full story at GlobeNewswire Inc. ↗IntelliStock summarizes and links to the original publisher. Data delayed 15 minutes.